Association of Brain Amyloidosis with the Incidence and Frequency of Neuropsychiatric Symptoms in ADNI: a Multisite Observational Cohort Study

Overview

Journal BMJ Open

Specialty General Medicine

Date 2019 Dec 21

PMID 31857304

Citations 28

Authors

Naira Goukasian

Kristy S Hwang

Tamineh Romero

Jonathan Grotts

Triet M Do

Jenna R Groh

Daniel R Bateman

Liana G Apostolova

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the relationship between amyloid burden and frequency of existing and incidence of new neuropsychiatric symptoms (NPS) in elderly with and without cognitive decline.

Methods: 275 cognitively normal controls (NC), 100 subjective memory complaint (SMC), 559 mild cognitive impairment (MCI) and 143 Alzheimer's disease dementia subjects from the Alzheimer's Disease Neuroimaging Initiative received (F)-florbetapir positron emission tomography (PET) scans. Yearly neuropsychiatric inventory (Neuropsychiatric Inventory (NPI)/NPI-Questionnaire) data were collected from the study partners at each visit. Mean standard uptake volume ratios (SUVR) normalised to whole cerebellum were obtained. Positive amyloid PET scan was defined as mean SUVR ≥1.17. Fisher's exact test was used to compare frequency and incidence between amyloid positive and amyloid negative subjects. Survival analyses were used to estimate of neuropsychiatric symptoms (NPS) between amyloid positive and amyloid negative subjects. Survival analyses were used to estimate hazard ratios for developing the most common NPS by amyloid status.

Results: No differences in NPS frequency were seen between amyloid positive and amyloid negative NC, SMC, MCI or dementia groups. MCI subjects with amyloid pathology however tended to have greater frequency x severity (FxS) of anxiety, hallucinations, delusions, apathy, disinhibition, irritability, aberrant motor behavior, and appetite, but not agitation, depression, night-time disturbances, or elation. MCI subjects with amyloid pathology were at greater risk for developing apathy, anxiety and agitation over time. Baseline presence of agitation and apathy and new onset agitation, irritability and apathy predicted faster conversion to dementia among MCI subjects.

Conclusions: Amyloid pathology is associated with greater rate of development of new NPS in MCI. Anxiety and delusions are significant predictors of amyloid pathology. Agitation, irritability and apathy are significant predictors for conversion from MCI to dementia.

Citing Articles

Parallel changes in cognition, neuropsychiatric symptoms, and amyloid in cognitively unimpaired older adults and those with mild cognitive impairment.

De Vito A, Kunicki Z, Joyce H, Huey E, Jones R Alzheimers Dement. 2025; 21(2):e14568.

PMID: 39936256 PMC: 11815203. DOI: 10.1002/alz.14568.

sTREM2 in discordant CSF Aβ and p-tau181.

Li D, Mantyh W, Men L, Jain I, Glittenberg M, An B Alzheimers Dement (Amst). 2025; 17(1):e70072.

PMID: 39822286 PMC: 11736621. DOI: 10.1002/dad2.70072.

Plasma phosphorylated tau and neuropsychiatric symptoms in dementia with Lewy bodies.

Gibson L, Gonzalez M, Ashton N, Tovar-Rios D, Blanc F, Pilotto A Alzheimers Dement. 2024; 21(2):e14434.

PMID: 39732510 PMC: 11848415. DOI: 10.1002/alz.14434.

The neural basis of neuropsychiatric symptoms in Alzheimer's disease.

Zhang N, Zhang S, Zhang L, Tao H, Zhang G Front Aging Neurosci. 2024; 16:1487875.

PMID: 39703925 PMC: 11655510. DOI: 10.3389/fnagi.2024.1487875.

Emerging Pharmacological Approaches for Psychosis and Agitation in Alzheimer's Disease.

Imbimbo C, Ramusino M, Leone S, Mazzacane F, De Franco V, Gatti A CNS Drugs. 2024; 39(2):143-160.

PMID: 39623197 PMC: 11769872. DOI: 10.1007/s40263-024-01133-9.

References

Rosenberg P, Mielke M, Appleby B, Oh E, Geda Y, Lyketsos C . The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease. Am J Geriatr Psychiatry. 2013; 21(7):685-95. PMC: 3428504. DOI: 10.1016/j.jagp.2013.01.006. View

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

Zufferey V, Donati A, Popp J, Meuli R, Rossier J, Frackowiak R . Neuroticism, depression, and anxiety traits exacerbate the state of cognitive impairment and hippocampal vulnerability to Alzheimer's disease. Alzheimers Dement (Amst). 2017; 7:107-114. PMC: 5476972. DOI: 10.1016/j.dadm.2017.05.002. View

Weiner M, Veitch D, Aisen P, Beckett L, Cairns N, Cedarbaum J . Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimers Dement. 2015; 11(7):865-84. PMC: 4659407. DOI: 10.1016/j.jalz.2015.04.005. View

Pink A, Stokin G, Bartley M, Roberts R, Sochor O, Machulda M . Neuropsychiatric symptoms, APOE ε4, and the risk of incident dementia: a population-based study. Neurology. 2015; 84(9):935-43. PMC: 4351664. DOI: 10.1212/WNL.0000000000001307. View

Steinberg M, Shao H, Zandi P, Lyketsos C, Welsh-Bohmer K, Norton M . Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2007; 23(2):170-7. PMC: 2932652. DOI: 10.1002/gps.1858. View

Dubois B, Hampel H, Feldman H, Scheltens P, Aisen P, Andrieu S . Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016; 12(3):292-323. PMC: 6417794. DOI: 10.1016/j.jalz.2016.02.002. View

Lyketsos C, Steinberg M, Tschanz J, Norton M, Steffens D, Breitner J . Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000; 157(5):708-14. DOI: 10.1176/appi.ajp.157.5.708. View

Donovan N, Amariglio R, Zoller A, Rudel R, Gomez-Isla T, Blacker D . Subjective cognitive concerns and neuropsychiatric predictors of progression to the early clinical stages of Alzheimer disease. Am J Geriatr Psychiatry. 2014; 22(12):1642-51. PMC: 4145054. DOI: 10.1016/j.jagp.2014.02.007. View

10.

Palmer K, Di Iulio F, Varsi A, Gianni W, Sancesario G, Caltagirone C . Neuropsychiatric predictors of progression from amnestic-mild cognitive impairment to Alzheimer's disease: the role of depression and apathy. J Alzheimers Dis. 2010; 20(1):175-83. DOI: 10.3233/JAD-2010-1352. View

11.

Fleisher A, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N . Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011; 68(11):1404-11. DOI: 10.1001/archneurol.2011.150. View

12.

Clark C, Schneider J, Bedell B, Beach T, Bilker W, Mintun M . Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011; 305(3):275-83. PMC: 7041965. DOI: 10.1001/jama.2010.2008. View

13.

Gaugler J, Yu F, Krichbaum K, Wyman J . Predictors of nursing home admission for persons with dementia. Med Care. 2009; 47(2):191-8. DOI: 10.1097/MLR.0b013e31818457ce. View

14.

Babulal G, Ghoshal N, Head D, Vernon E, Holtzman D, Benzinger T . Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels. Am J Geriatr Psychiatry. 2016; 24(11):1095-1104. PMC: 5069099. DOI: 10.1016/j.jagp.2016.04.004. View

15.

Petersen R, Aisen P, Beckett L, Donohue M, Gamst A, Harvey D . Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010; 74(3):201-9. PMC: 2809036. DOI: 10.1212/WNL.0b013e3181cb3e25. View

16.

Weiner M, Veitch D, Aisen P, Beckett L, Cairns N, Green R . Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. Alzheimers Dement. 2017; 13(4):e1-e85. PMC: 6818723. DOI: 10.1016/j.jalz.2016.11.007. View

17.

Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E . 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010; 68(3):319-29. DOI: 10.1002/ana.22068. View

18.

Rabins P, Schwartz S, Black B, Corcoran C, Fauth E, Mielke M . Predictors of progression to severe Alzheimer's disease in an incidence sample. Alzheimers Dement. 2012; 9(2):204-7. PMC: 3791880. DOI: 10.1016/j.jalz.2012.01.003. View

19.

Saykin A, Wishart H, Rabin L, Santulli R, Flashman L, West J . Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology. 2006; 67(5):834-42. PMC: 3488276. DOI: 10.1212/01.wnl.0000234032.77541.a2. View

20.

Weiner M, Veitch D, Aisen P, Beckett L, Cairns N, Cedarbaum J . 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement. 2015; 11(6):e1-120. PMC: 5469297. DOI: 10.1016/j.jalz.2014.11.001. View